Rakovina Therapeutics to Present Brain-Penetrant ATR Inhibitor Data at the 31st Society for Neuro-Oncology Annual Meeting

Source: The Manila times
Published on: 2026-11-05 10:45

Poster to highlight AI-designed kt-5000AI compounds developed for PTEN-deficient brain tumours VANCOUVER, British Columbia, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced that new preclinical data from its kt-5000AI ATR inhibitor program will be presented in a poster at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day, taking place November 12-15, 2026, in Philadelphia, Pennsylvania. The poster describes brain-penetrant inhibitors of ataxia telangiectasia and Rad3-related protein kinase (ATR) developed with Variational AI Inc. ("Variational AI") using its Enki™ generative AI platform. The compounds were designed for tumours that have lost the tumour-suppressor gene PTEN, a vulnerability foun...

(Please login to view full article)

Third-Party Content Disclaimer

Content displayed on this platform may include news articles, reports, and other materials aggregated from publicly available third-party sources through automated tools. Such content is not created, written, commissioned, or edited by Straits Interactive Pte Ltd or the Data Protection Excellence (DPEX) Network.

While we take reasonable steps to ensure responsible publication, we do not independently verify all third-party information and make no representations as to its accuracy, completeness, or reliability.

The views, findings, and statements expressed in third-party content belong solely to the original source and do not reflect the views of Straits Interactive Pte Ltd or the DPEX Network.

If you believe any content is inaccurate, infringing, or should be removed, please contact us at legal@straitsinteractive.com. We will review the matter and, where appropriate, take action in accordance with our internal policies.

Unlock these benefits
globe

Get access to news, enforcement cases, events, and actionable tips and guides

email

Get regular email updates and offers

job

Job opportunities, mentorship and career guidance

discuss

Exclusive access to Data Protection community - ask questions, network and share knowledge with peers and experts via WhatsApp and Linkedin